KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Impact of Setmelanotide on Metabolic Syndrome Risk in Patients With Bardet-Biedl Syndrome.

Andrea M Haqq, Christine Poitou, Wendy K Chung, Elizabeth Forsythe, Rushika Conroy, Hélène Dollfus, Sonali Malhotra, Nicolas Touchot, Uzoma Okorie, Philip Beales, Karine Clément, Jesús Argente

J Clin Endocrinol Metab 110(10) e3271-e3282

PMID39919037
PMCIDPMC12448622
DOI10.1210/clinem/dgaf079
发表日期2025-02-07
入排依据:未发现恶性肿瘤人群证据。
已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:森林图/亚组分析图。
摘要

摘要

CONTEXT: Bardet-Biedl syndrome (BBS) is a rare genetic disease associated with disruptions in melanocortin-4 receptor pathway signaling that can contribute to increased risk for metabolic syndrome and obesity-related comorbidities. OBJECTIVE: Here, MetS-Z-BMI scores, a continuous measure based on body mass index (BMI), were calculated to determine metabolic syndrome severity and response to treatment with the melanocortin-4 receptor agonist setmelanotide in BBS. METHODS: All patients from a phase 3 study (NCT03746522) of setmelanotide with data required for the calculation of MetS-Z-BMI scores were included. Mean MetS-Z-BMI score was determined at baseline and Week 52; subgroup analyses were conducted by sex, age, genotype, and response to setmelanotide. RESULTS: MetS-Z-BMI scores were evaluable for 22 of 32 patients enrolled. Baseline mean (SD) MetS-Z-BMI score across patients was 1.1 (0.5); baseline mean (SD) odds ratios of future cardiovascular disease or type 2 diabetes were 3.1 (1.5) and 3.7 (1.7), respectively, for adults and 10.2 (4.7) and 2.8 (1.3), respectively, for pediatric patients. Overall, mean (SD) MetS-Z-BMI score at Week 52 was reduced by 0.34 (0.62). Mean (SD) MetS-Z-BMI scores significantly differed depending on achievement of predetermined weight-based thresholds of ≥10% weight loss (patients aged ≥18 years) or ≥0.3-point reduction in BMI Z score (patients aged <18 years) at Week 52 (achievers, -0.64 [0.54]; nonachievers, 0.08 [0.47]; P = .0043). No significant difference was observed with other subgroup comparisons. CONCLUSION: MetS-Z-BMI score reductions were observed after 52 weeks of treatment, suggesting that setmelanotide may decrease metabolic syndrome severity and risk of future obesity-related comorbidities in those with BBS.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. Distribution of MetS-Z-BMI score change from baseline at Week 52. MetS-Z-BMI, metabolic syndrome severity based on body mass index.
非 KM Figure
Figure 2Figure 2. Change from baseline based on weight response with setmelanotide treatment. ( A ) Percent change in weight (top) and change in MetS-Z-BMI score (bottom) in adult patients. ( B ) Change in BMI Z score (top) and MetS-Z-BMI score (bottom) for pediatric patients. The same individual is aligned across top and bottom parts of each panel representing the distribution of individual change from baseline at Week 52. MetS-Z-BMI, metabolic syndrome severity based on body mass index.
非 KM Figure
Figure 3Figure 3. Comparison of mean Met-Z-BMI score at baseline and Week 52 within subgroups of ( A ) 1-year weight threshold, ( B ) genotype, ( C ) sex, and ( D ) age. *Significant difference between groups. Absolute difference is reported for each subgroup analysis. Error bars are the SD. P values were calculated using a 2-sided 2-sample t test. Analysis of genotype did not include patients with BBS2 (n = 2) or MKKS (n = 1).
非 KM Figure